MIRA Pharma Prices 1.275M Share IPO at $7/sh

This post was originally published on this site

The Company has granted the underwriter a 45-day option to purchase up to 191,250 additional shares of common stock at the initial public offering price, less underwriting discounts and commissions, to cover over-allotments, if any.

The offering is expected to close on August 7, 2023, subject to customary closing conditions.

In connection with the offering, the Company has received approval to have the shares of its common stock listed on the Nasdaq Capital Market, with the shares expected to begin trading on August 3, 2023 under the symbol “MIRA”.

The Company expects to use the net proceeds from the offering to advance its clinical development programs and for working capital and general corporate purposes.

Kingswood Investments, division of Kingswood Capital Partners, LLC is acting as sole bookrunner for the offering.

A registration statement on Form S-1 (File No. 333-273024) relating to the securities was filed with the Securities and Exchange Commission (“SEC“) and was declared effective by the SEC on August 2, 2023. This offering is being made only by means of a prospectus. A final prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. Electronic copies of the final prospectus relating to this offering, when available, may be obtained from Kingswood Investments, 1111 Brickell Avenue, Suite 1820, Miami, Florida 33131, or by email at Syndicate@KingswoodUS.com.